UTHR Relative Valuation
UTHR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, UTHR is overvalued; if below, it's undervalued.
Historical Valuation
United Therapeutics Corp (UTHR) is now in the Overvalued zone, suggesting that its current forward PE ratio of 16.92 is considered Overvalued compared with the five-year average of 12.31. The fair price of United Therapeutics Corp (UTHR) is between 350.00 to 435.50 according to relative valuation methord. Compared to the current price of 483.50 USD , United Therapeutics Corp is Overvalued By 11.02%.
Relative Value
Fair Zone
350.00-435.50
Current Price：483.50
11.02%
Overvalued
17.03
PE
1Y
3Y
5Y
Trailing
Forward
9.86
EV/EBITDA
United Therapeutics Corp. (UTHR) has a current EV/EBITDA of 9.86. The 5-year average EV/EBITDA is 6.63. The thresholds are as follows: Strongly Undervalued below 3.77, Undervalued between 3.77 and 5.20, Fairly Valued between 8.06 and 5.20, Overvalued between 8.06 and 9.49, and Strongly Overvalued above 9.49. The current Forward EV/EBITDA of 9.86 falls within the Strongly Overvalued range.
10.00
EV/EBIT
United Therapeutics Corp. (UTHR) has a current EV/EBIT of 10.00. The 5-year average EV/EBIT is 6.63. The thresholds are as follows: Strongly Undervalued below 3.33, Undervalued between 3.33 and 4.98, Fairly Valued between 8.28 and 4.98, Overvalued between 8.28 and 9.93, and Strongly Overvalued above 9.93. The current Forward EV/EBIT of 10.00 falls within the Strongly Overvalued range.
6.17
PS
United Therapeutics Corp. (UTHR) has a current PS of 6.17. The 5-year average PS is 4.77. The thresholds are as follows: Strongly Undervalued below 3.61, Undervalued between 3.61 and 4.19, Fairly Valued between 5.35 and 4.19, Overvalued between 5.35 and 5.93, and Strongly Overvalued above 5.93. The current Forward PS of 6.17 falls within the Strongly Overvalued range.
12.60
P/OCF
United Therapeutics Corp. (UTHR) has a current P/OCF of 12.60. The 5-year average P/OCF is 10.28. The thresholds are as follows: Strongly Undervalued below 7.58, Undervalued between 7.58 and 8.93, Fairly Valued between 11.62 and 8.93, Overvalued between 11.62 and 12.97, and Strongly Overvalued above 12.97. The current Forward P/OCF of 12.60 falls within the Overvalued range.
15.87
P/FCF
United Therapeutics Corp. (UTHR) has a current P/FCF of 15.87. The 5-year average P/FCF is 12.43. The thresholds are as follows: Strongly Undervalued below 8.76, Undervalued between 8.76 and 10.60, Fairly Valued between 14.27 and 10.60, Overvalued between 14.27 and 16.11, and Strongly Overvalued above 16.11. The current Forward P/FCF of 15.87 falls within the Overvalued range.
United Therapeutics Corp (UTHR) has a current Price-to-Book (P/B) ratio of 3.13. Compared to its 3-year average P/B ratio of 2.26 , the current P/B ratio is approximately 38.53% higher. Relative to its 5-year average P/B ratio of 2.28, the current P/B ratio is about 37.54% higher. United Therapeutics Corp (UTHR) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 6.51%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 6.65% , the current FCF yield is about -100.00% lower.
3.15
P/B
Median3y
2.26
Median5y
2.28
5.42
FCF Yield
Median3y
6.51
Median5y
6.65
Competitors Valuation Multiple
The average P/S ratio for UTHR's competitors is , providing a benchmark for relative valuation. United Therapeutics Corp Corp (UTHR) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 6.76%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of UTHR increased by 37.20% over the past 1 year. The primary factor behind the change was an increase in P/E Change from 14.36 to 18.35.
The secondary factor is the Revenue Growth, contributed 6.76%to the performance.
Overall, the performance of UTHR in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is United Therapeutics Corp (UTHR) currently overvalued or undervalued?
What is United Therapeutics Corp (UTHR) fair value?
How does UTHR's valuation metrics compare to the industry average?
What is the current P/B ratio for United Therapeutics Corp (UTHR) as of Dec 05 2025?
What is the current FCF Yield for United Therapeutics Corp (UTHR) as of Dec 05 2025?
What is the current Forward P/E ratio for United Therapeutics Corp (UTHR) as of Dec 05 2025?